Re ding medicine: shout out the next 5 years of revenue CAGR 50%

On May 8,2024, Zaiding Pharmaceutical announced the financial results of 24Q1, and on May 9, it directly closed with a 20 + CM increase. This was the first time since Zaiding Pharmaceutical was listed in Hong Kong in 2020.

In the past, the quarterly growth rate is higher than 24Q1, such as 21Q1 and 21Q2. However, due to the huge bubble formed by a variety of factors, even if the revenue is growing steadily, the overall trend of the stock price in recent years is still mainly falling.

Means that the current bubble of Zading Pharmaceutical is basically cleared, and the future stock price trend is highly related to the revenue situation.

Zamedicine in 2023 annual report in the end of 2025 or will reach profitability, from the following expenses, Zading medicine has been working in this aspect.

However, under the license in model, it will bear the high cost of products that have not yet been localized. The average gross profit margin of ZaPharmaceutical is about 65%, more than ten or twenty points lower than its peers.

In order to make up for the gap in a short time (2025), we must rely on explosive products to achieve it. Then will there be explosive products in these two years?

We have commented on the planet ZS.

Driven by the performance of 24Q1, from the historical sales of the following 5 commercial varieties, 3 varieties of 24Q1 hit a quarterly record high, of which 2 varieties are more than 2 years of sales.

PARP inhibitor, the company explained the increase in sales, treatment duration and renewal of medical insurance; the company expects the continuous recovery of all treated patients in 2024; the company explained that the oral dosage form was included in the medical insurance; the FcRn inhibitor, the company explained the positive feedback from doctors and patients, hospital access and medical insurance, with the estimated sales volume of $70 million in 2024.

In such an optimistic scenario, management has proposed a five-year CAGR of 50% to generate $2 billion in revenue by 2028.

From 23Q4 shouted out the profit balance at the end of 25, to 24Q1 shouted out 28 years of revenue of 2 billion dollars, very looking forward to 24Q2 will have what new expectations.

The following figure is the summary of the two recent catalysts of Ziding Medicine. In addition to the recent approval of the ROS 1 inhibitor reptinib, the antibiotic SUL-DUR treatment ABC was approved in 2024, with no significant delay. 24Q4 also includes the readout of the top line data of electric field treatment of pancreatic cancer phase 3.

Author: Rich Venture capital Link: https://xueqiu.com/7742989740/290115471 Source: Snowball The copyright belongs to the author.

Commercial reprint, please contact the author to obtain authorization, non-commercial reprint, please indicate the source.

Risk tips: The views mentioned in this article only represent the personal opinions, the target involved is not recommended, according to the sale, the risk.